deltatrials
Terminated PHASE3 NCT00124839

Naltrexone in Borderline Personality Disorder

Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Borderline Personality Disorder
Interventions Naltrexone
Updated 5 times since 2017 Last updated: Apr 14, 2008 Started: Oct 31, 2005 Primary completion: Oct 31, 2007 Completion: Mar 31, 2008

This PHASE3 trial investigates Borderline Personality Disorder and is currently terminated or withdrawn. Central Institute of Mental Health, Mannheim leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Central Institute of Mental Health, Mannheim
Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bad Wiessee, Germany
  • • Cologne, Germany
  • • Mannheim, Germany
  • • Rostock, Germany
  • • Simbach, Germany